1. Molecular‐targeted agents for advanced gastric cancer.
| Molecular target | Mechanism of action | Targeted agent | Phase of development | |
| EGFR‐targeting agent | Anti‐EGFR mAb | Cetuximab | III | |
| Panitumumab | III | |||
| EGFR TKIs | Erlotinib | II | ||
| Gefitinib | II | |||
| Anti‐HER‐2 mAb | Trastuzumab | III | ||
| HER‐2 and EGFR TKI | Lapatinib | III | ||
| VEGF‐targeting agent | Anti‐VEGF mAb | Bevacizumab | III | |
| Anti‐VEGFR mAb | Ramucirumab | III | ||
| VEGFR TKI | MTI, targeted on VEGFR, PDGFR and Raf | Sunitinib | II | |
| Sorafenib | II | |||
| MTI, targeted on VEGFR, PDGFR and c‐Kit | Cediranib | II | ||
| mainly targeted on VEGFR‐2 | Apatinib | III | ||
| P13K/mTOR‐targeting agent | mTOR inhibitor | Everolimus | III | |
| HGF/MET‐targeting agent | MET TKI | Foretinib | I‐II | |
| Crizotinib | I‐II | |||
| anti‐MET antibody | Onartuzumab | II | ||
| anti‐HGF antibody | Rilotumumab | III | ||
| MMP‐targeting agent | MMP inhibitor | Marimastat | III | |
| FGF‐targeting agent | FGFR inhibitor | AZD 4547 | II | |
| dual inhibitor of FGF and VEGF | Brivanib | II | ||
| HDAC‐targeting agent | HDAC inhibitor | Vorinostat | I‐II | |
| EpCAM‐targeting agent | Trifuctional bispecific antibody | Catumaxomab | II | |
EGFR: epidermal growth factor receptor; FGF: fibroblast growth factor; FGFR: fibroblast growth factor receptor; HDAC: histone deacetylase; HGF: hepatocyte growth factor; mAb: monoclonal antibodies; MMP: matrix metalloproteinase; MTI: multi‐targeted TKI; mTOR: mammalian target of rapamycin; PDGFR: platelet derived growth factor receptor; TKI: tyrosine kinase inhibitor; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor